When experiments travel: Clinical trials and the global search for human subjects

When Experiments Travel: Clinical Trials and the Global Search for Human Subjects

Volumn , Issue , 2009, Pages

  Petryna, Adriana ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85083925488     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (406)

1. Aaby, Peter, et al. 1997. "Ethics of HIV Trials." Lancet 350(9090):1546.
2. Abadie, Roberto. 2009. A Guinea Pig's Wage: Risk, Body Commodifications, and the Ethics of Pharmaceutical Research in America. Durham, NC: Duke University Press.
3. Abbasi, Kamran. 2005. "Developing European Clinical Research in the Interest of Patients and Public Health." PowerPoint presentation, Brussels.
4. Abraham, John. 2007. "Drug Trials and Evidence Bases in International Regulatory Context." Biosocieties 2:41-57.
5. Abramson, John. 2004. Overdo$ed America: The Broken Promise of American Medicine. New York: Harper Perennial.
6. ACHRE [Advisory Committee on Human Radiation Experiments]. 1996. "Final Report of the Advisory Committee on Human Radiation Experiments." Washington, DC: U.S. Government Printing Office.
7. Adams, Vincanne. 2003. "Randomized Controlled Crime: Postcolonial Sciences in Alternative Medicine Research." Social Studies of Science 32(5-6):659-690.
8. Alden, Edward. 2004. "US Interrogation Debate: Dismay at Attempt to Find Legal Justification for Torture." Financial Times, June 10, 3.
9. Amaral, K. M., J. G. Reis, and P. D. Picon. 2000. "Atenção Farmacêutica no Sistema Único de Saúde: Um Exemplo de Experiência bem Sucedida com Patientes Portadores de Hepatite C." Revista Brasileira de Farmácia 87:19-21.
10. Anand, Geeta. 2005. "Why Genzyme Can Charge So Much for Cerezyme." Wall Street Journal, November 16, A15.
11. Anderson, Warwick. 2003. The Cultivation of Whiteness: Science, Health, and Racial Destiny in Australia. New York: Basic Books.
12. Angell, Marcia. 1988. "Ethical Imperialism? Ethics in International Collaborative Clinical Research." New England Journal of Medicine 319(16):1081-1083.
13. Angell, Marcia. 1997. "The Ethics of Clinical Research in the Third World." New England Journal of Medicine 337(12):847-849.
14. Angell, Marcia. 2000. "Investigators' Responsibilities for Human Subjects in Developing Countries." New England Journal of Medicine 342(13):967-968.
15. Angell, Marcia. 2004. "The Truth about the Drug Companies." New York Review of Books 51(12). Available at http://www.nybooks.com/articles/17244.
16. Angell, Marcia. 2005. The Truth about the Drug Companies: How They Deceive Us and What to Do about It. New York: Random House.
17. Angell, Marcia. 2006. "Your Dangerous Drugstore." New York Review of Books 53(10). Retrieved February 2007, from http://www.nybooks.com/articles/19055.
18. Annas, G. L., L. H. Glantz, and B. F. Katz. 1977. Informed Consent to Human Experimentation: The Subject's Dilemma. Cambridge, MA: Ballinger.
19. Applbaum, Kalman. 2006. "American Pharmaceutical Companies and the Adoption of SSRI's in Japan." In Global Pharmaceuticals: Ethics, Markets, Practices, edited by Adriana Petryna, Andrew Lakoff, and Arthur Kleinman, 85-111. Durham, NC: Duke University Press.
20. "Arexis AB: Arexis obtains orphan drug designation in the EU for novel cystic fibrosis therapy." 2005. Press Release. Innovations Kapital. Retrieved from http://www.innkap.se/PressRelease.aspx?page=5&press=173.
21. Arnold, David. 1993. Colonizing the Body: State Medicine and Epidemic Disease in Nineteenth-Century India. Berkeley and Los Angeles: University of California Press.
22. Austin, CenterWatchG. Breitenstein, Kent Buse, Laura Frost, Tomoko Fujisaki, Adetokunbo Lucas, Sheila McCarthy, William Muraskin, Clement Roberts, Marc Roberts, and Gill Walt. 2002. Public-Private Partnerships for Public Health. Edited by Michael R. Reich. Harvard Center for Population and Development Studies.
23. Avorn, Jerry. 2004. PowerfulMedicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Knopf.
24. Azoulay, Pierre. 2003. "Agents of Embeddedness." NBER working paper 10142. December 2003. Cambridge, MA: National Bureau of Economic Research. Available at http://www.nber.org/papers/w10142.
25. Bailey, Kent. 1994. "Generalizing the Results of Randomized Clinical Trials." Controlled Clinical Trials 15:15-23.
26. Bannerjee, Abhijit, Angus Deaton, and Esther Duflo. 2004. "Wealth, Health, and Health Services in Rural Rajasthan." Poverty Action Lab Paper No. 8. Available at http://www.povertyactionlab.com.
27. Barnes, Kirsty. 2007. "PharmaNet to suffer formal SEC scrutiny." DrugResearcher.com. March 21, 2007. http://www.drugresearcher.com/news/,downloaded December 2007.
28. Barry, Andrew. 2001. Political Machines: Governing a Technological Society. London and New York: Athlone Press.
29. Barry, Andrew, and Don Slater, eds. 2005. The Technological Economy. London and New York: Routledge.
30. Bayer, R. 1998. "The Debate over Maternal-Fetal HIV Transmission Prevention Trials in Africa, Asia, and Caribbean: Racist Exploitation or Exploitation of Racism?" American Journal of Public Health 88(4):567-570.
31. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. 1979. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Washington, DC: Department of Health, Education and Welfare.
32. Benatar, Solomon. 2001. "Distributive Justice and Clinical Trials in the Third World." Theoretical Medicine and Bioethics 22(3):169-176.
33. Benatar, Solomon, and Peter A. Singer. 2000. "A New Look at International Research Ethics." British Medical Journal 321(7264):824-826.
34. Berenson, Alex. 2007. "Plaintiffs Find Payday Elusive in Vioxx Cases." New York Times, August 21, A1, A17.
35. Berenson, Alex. 2008. "Study Reveals Doubt on Drug for Cholesterol." New York Times, January 15, A1, A16.
36. Beutler, Ernest. 1994. "Economic Malpractice in the Treatment of Gaucher's Disease." American Journal of Medicine 97(1):1-2.
37. Beutler, Ernest. 2004. "Enzyme Replacement in Gaucher Disease." PLoS Medicine 1(2): 118-121.
38. Biao, Xiang. 2006. Global "Body Shopping": An Indian Labor System in the Information Technology Industry. Princeton: Princeton University Press.
39. Biehl, João. 2001. "Technology and Affect: HIV/AIDS Testing in Brazil." Culture, Medicine and Psychiatry 25(1):87-129.
40. Biehl, João. 2005. Vita: Life in a Zone of Social Abandonment. Berkeley and Los Angeles: University of California Press.
41. Biehl, João. 2006. "Pharmaceutical Governance." In Global Pharmaceuticals: Ethics, Markets, Practices, edited by Adriana Petryna, Andrew Lakoff, and Arthur Kleinman, 206-240. Durham, NC: Duke University Press.
42. Biehl, João. 2007. Will to Live: AIDS Therapies and the Politics of Survival. Princeton: Princeton University Press.
43. Bodenheimer, Thomas. 2000. "Uneasy Alliance-Clinical Investigators and the Pharmaceutical Industry." New England Journal of Medicine 342(20):1539-1544.
44. Bombardier, C., L. Laine, A. Reicin, et al. 2000. "Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis." New England Journal of Medicine 343:1520-1528.
45. Bosk, Charles. 1999. "Professional Ethicist Available: Logical, Secular, Friendly. Bioethics and Beyond." Daedalus 128(4):47-68.
46. Bosk, Charles. 2002. "Now That We Have the Data, What Was the Question?" American Journal of Bioethics 2(4):21-23.
47. Bosk, Charles. 2005. What Would You Do? The Collision of Ethnography and Ethics. Chicago: University of Chicago Press.
48. Bosk, Charles. 2007. "The New Bureaucracies of Virtue or When Form Fails to Follow Function." PoLAR: Political and Legal Anthropology Review 30(2):192-209.
49. Bosk, Charles, and Raymond de Vries. 2004. "Bureaucracies of Mass Deception: Institutional Review Boards and the Ethics of Ethnographic Research." Annals of the American Academy of Political and Social Science 595(1):249-263.
50. Botbol-Baum, Mylene. 2000. "The Shrinking of Human Rights: The Controversial Revision of the Helsinki Declaration." HIV Medicine 1(4):238-245.
51. Bowker, Geoffrey C., and Susan Leigh Star. 1999. Sorting Things Out: Classification and Its Consequences. Cambridge, MA: MIT Press.
52. Brada, Betsey. 2004. "Bodies of Evidence: The Emergence of AIDS Clinical Trials Group (ACTG) 076." Newsletter of the AIDS and Anthropology Research Group 16(2):7-8.
53. "Brand of the Year-Gleevec." 2004. Med Ad News 23(5):5.
54. Brandt, Allan M. 1978. "Racism and Research: The Case of the Tuskegee Syphilis Study." Hastings Center Report 8(6):21-29.
55. Brandt, Allan M. 1985. No Magic Bullet A Social History of Venereal Disease in the United States since 1880. New York: Oxford University Press.
56. Briggs, Charles, and Clara Mantini-Briggs. 2003. Stories in the Time of Cholera: Racial Profiling during a Medical Nightmare. Berkeley and Los Angeles: University of California Press.
57. Brody, Baruch. 1995. Ethical Issues in Drug Testing, Approval, and Pricing: The Clot-Dissolving Drugs. New York: Oxford University Press.
58. Brody, Baruch. 2002. "Ethical Issues in Clinical Trials in Developing Countries." Statistics in Medicine 21:2853-2858.
59. Brody, Howard. 2007. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Lanham, MD: Rowman & Littlefield.
60. Buekens, Pierre, Gerald Keusch, Jose Belizan, and Zulfiqar Ahmed Bhutta. 2004. "Evidence-Based Global Health." Journal of the American Medical Association 291(21):2639-2641.
61. Callahan, Daniel. 2003. What Price Better Health? Hazards of the Research Imperative. Berkeley and Los Angeles: University of California Press.
62. Canavan, Neil. 2008. "The Trouble with Trials." Drug Discovery & Development, March 1.
63. Canguilhem, Georges. 1991. The Normal and the Pathological. New York: Zone Books.
64. Caplan, Arthur. "Commentary: Report Paints Grim Picture of Drug Trial Safety." September 28, 2007. http://www.msnbc.msn.com/id/21029879/,down loaded October 5, 2007.
65. Carpenter, Dan. In press. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA.
66. CenterWatch. 2005. State of the Clinical Trials Industry: A Sourcebook of Charts and Statistics. Boston: Thomson CenterWatch.
67. CenterWatch. 2007. "Glossary." Retrieved from http://www.centerwatch.com/patient/glossary.html#N.
68. CenterWatch. 2008. State of the Clinical Trials Industry: A Sourcebook of Charts and Statistics. Boston: Thomson CenterWatch.
69. "CenterWatch Launches First-of-Its-Kind Consumer Guide to the Risks and Bene fits of Volunteering for Clinical Trials." 2002. Retrieved September 1, 2004, from http://www.centerwatch.com/newsreleases/4-11-2002.html.
70. Chadwick, Gary. 1997. "Historical Perspective: Nuremberg, Tuskegee, and the Radiation Experiments." Journal of the International Association of Physicians in AIDS Care 3(1):27-28.
71. Chambliss, Daniel F. 1996. Beyond Caring: Hospitals, Nurses, and the Social Organization of Ethics. Chicago: University of Chicago Press.
72. Cherry, Brenda. 2005. "Drug Testing Goes Offshore." Fortune 8:66.
73. Cherry, Donald, David Woodwell, and Elizabeth Rechtsteiner. 2005. "National Ambulatory Medical Care Survey 2005 Summary." Division of Health Care Statistics, CDC. http://www.cdc.gov/nchs/data/ad/ad387.pdf.
74. Christakis, Nicholas. 1992. "Ethics Are Local: Engaging Cross-Cultural Variation in the Ethics for Clinical Research." Social Science and Medicine 35(9):1079-1091.
75. "Clinical Trials and Protection of Trial Subjects in Low-Income and Developing Countries." November 6, 2007. Final Report of the expert meeting, European Parliament and WEMOS. http://www.wemos.nl/Documents/report_expert_meeting_clinical_trials.pdf.
76. The Clinical Trials Business. 2003. Report B-171. Norwalk, CT: Business Communication Co.
77. ClinPage. 2007. "NEJM Indicts CROs." October 18. http://www.clinpage.com/article/nejm_indicts_cros/.
78. Cohen, Carl. 1978. "Medical Experimentation on Prisoners." Perspectives in Biology and Medicine 21:357-372.
79. Cohen, Jon. 2006. "The New World of Global Health." Science 311(5758):162-167.
80. Cohen, Lawrence. 1999. "Where It Hurts: Indian Material for an Ethics of Organ Transplantation. Daedalus 128(4):135-165.
81. Comaroff, John, and Jean Comaroff. 1992. "Medicine, Colonialism, and the Black Body." In Ethnography and the Historical Imagination, edited by Jean Comaroff and John Comaroff, 215-235. Boulder, CO: Westview Press.
82. Comaroff, John, and Jean Comaroff. 2006. Law and Disorder in the Postcolony. Chicago: University of Chicago Press.
83. "Comments on the Draft Health and Human Services Inspector General's Report: The Globalization of Clinical Trials." 2001. (OEI-01-00-00190) (HRG Publication #1591). Public Citizen's Health Research Group. July 5, 2001. Retrieved December 12, 2003, from http://www.citizen.org/publications/release.cfm?ID=7087&secID=1158&catID=126.
84. Cook-Deegan, Robert, and Tom Dedeurwaerdere. 2006. "The Science Commons in Life Science Research: Structure, Function, and Value of Access to Genetic Diversity." International Social Science Journal 58(188):299-317.
85. "CRO Industry at a Glance." 2007. Association of Clinical Research Organizations. Retrieved from http://www.acrohealth.org/industry-ataglance.php.
86. Crouch, Robert A., and John D. Arras. 1998. "AZT Trials and Tribulations." Hastings Center Report 28(6):26-34.
87. Daemmrich, Arthur A. 2004. Pharmacopolitics: Drug Regulation in the United States and Germany. Chapel Hill: University of North Carolina Press.
88. Das, Veena. 1995. "Suffering, Legitimacy, and Healing: The Bhopal Case." In Critical Events: An Anthropological Perspective on Contemporary India. Delhi: Oxford University Press.
89. Das, Veena. 1999. "Public Good, Ethics, and Everyday Life: Beyond the Boundaries of Bioethics." Daedalus 128(4):99-134.
90. Das, Veena, and Ranendra Das. 2006. "Pharmaceuticals in Urban Ecologies: The Register of the Local." In Global Pharmaceuticals: Ethics, Markets, Practices, edited by Adriana Petryna, Andrew Lakoff, and Arthur Kleinman, 171-206. Durham, NC: Duke University Press.
91. Davidoff, Frank, Catherine D. DeAngelis, Jeffrey M. Drazen, M. Gary Nicholls, John Hoey, Liselotte Højgaard, Richard Horton, Sheldon Kotzin, Magne Nylenna, A. Overbeke, Harold C. Sox, Martin Weyden, and Michael S. Wilkes. 2001. "Sponsorship, Authorship and Accountability" Journal of the American Medical Association 286(10):1232-1234.
92. Davies, Norman. 2005. Rising '44: The Battle for Warsaw. New York: Penguin.
93. DeAngelis, C. D., J. M. Drazen, F. A. Frizelle, et al. 2004. "Clinical Trial Regis-tration: A Statement from the International Committee of Medical Journal Editors." Journal of the American Medical Association 292:1363-1364.
94. DeAngelis, C. D., J. M. Drazen, F. A. Frizelle, et al. 2005. "Is This Clinical Trial Fully Registered? A Statement from the International Committee of Medical Journal Editors." Journal of the American Medical Association 293:2927-2929.
95. Decision Memorandum. 2005. Memorandum from John K. Jenkins, M.D., and Paul J. Seligman, M.D., M.P.H. through Steven Galson, M.D., M.P.H. 5, 9 n.5 (April 6, 2005), http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf.
96. DelVecchio Good, Mary-Jo. 2001. "The Biotechnical Embrace." Culture, Medicine and Psychiatry 25(4):395-410.
97. de Vries, Raymond. 2004. "How Can We Help? From 'Sociology in' to 'Sociology of ' Bioethics." Journal of Law, Medicine, and Ethics 32(2):279-293.
98. de Vries, Raymond, Adriana Petryna, Trudo Lemmens, Charles Bosk, and Jefferey Kahn. 2004. Research proposal manuscript: The Global Market in Human Subjects: The Needs of Multinational Corporations and the Rights of National Citizens.
99. de Zulueta, P. 2001. "Randomised Placebo-Controlled Trials and HIV-Infected Pregnant Women in Developing Countries: Ethical Imperialism or Unethical Exploitation?" Bioethics 15(4):289-311.
100. Dickersin, Kay, and Drummond Rennie. 2003. "Registering Clinical Trials." Journal of the American Medical Association 290(4):7.
101. DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. 2003. "The Price of Innovation: New Estimates of Drug Development Costs." Journal of Health Economics 22:151-185.
102. DNDWG [Drugs for Neglected Diseases Working Group]. 2001. "Fatal Imbalance: The Crisis in Research and Development for Drugs for Neglected Diseases." Geneva: MSF and DNDWG, downloadable at www.msf.org/source/access/2001/fatal/fatal.pdf.
103. Dodier, Nicolas. 2005. "Transnational Medicine in Public Arenas: AIDS Treatments in the South." Culture, Medicine and Psychiatry 29(3):285-307.
104. Donne, John. 2007. Selected Poems. New York: Penguin.
105. Dourada, M.I.C., M. A. Veras, D. Barreira, and A. M. de Brito. 2006. "AIDS Epidemic Trends after the Introduction of Antiretroviral Therapy in Brazil." Revista de Saúde Pública 40 (Suppl.):1-8.
106. Drinkard, Jim. 2005. "Drugmakers Go Furthest to Sway Congress." USA Today, April 25. Retrieved August 6, 2007, from http://www.usatoday.com/money/industries/health/drugs/2005-04-25-drug-lo bby-cover_x.htm.
107. Dumit, Joseph. 2000. "When Explanations Rest: 'Good Enough' Brain Science and the New Biomental Disorders." In Living and Working with the New Medical Technologies: Intersections of Inquiry, edited by Margaret Lock, Alan Young, and Alberto Cambrosio, 209-233. Cambridge: Cambridge University Press.
108. Dumit, Joseph. Forthcoming. Drugs for Life. Durham, NC: Duke University Press.
109. Dunn, Elizabeth. 2004. Privatizing Poland: Baby Food, Big Business, and the Remaking of Labor. Ithaca: Cornell University Press.
110. Ecks, Stefan. 2005. "Pharmaceutical Citizenship: Antidepressant Marketing and the Promise of Demarginalization in India." Anthropology & Medicine. 12(3):239-254.
111. Ecks, Stefan. 2008. "Global Pharmaceutical Markets and Corporate Citizenship." Biosocieties 3:165-181.
112. Ejembi, C. L., E. P. Renne, and H. A. Adamu. 1998. "The Politics of the 1996 Cerebrospinal Meningitis Epidemic in Nigeria." Africa: Journal of the International African Institute 68(1):118-134.
113. Elias, Paulo Eduardo M., and Amelia Cohn. 2003. "Health Reform in Brazil: Lessons to Consider." American Journal of Public Health 93(1):44-48.
114. Elliott, Carl. 2007. "We'll Test It on Them." American Prospect, March 18. Available at http://www.prospect.org/cs/articles?article=well_test_it_on_them.
115. Elliott, Carl. 2008. "Guinea Pigging." New Yorker, January 7.
116. Epstein, Helen. 2007. The Invisible Cure: Africa, the West, and the Fight against AIDS. New York: Farrar, Straus and Giroux.
117. Epstein, Steven. 1996. Impure Science: AIDS, Activism, and the Politics of Knowledge. Berkeley and Los Angeles: University of California Press.
118. Epstein, Steven. 2007. Inclusion: The Politics of Difference in Medical Research. Chicago: University of Chicago Press.
119. Etkin, Nina. 1999. "The Rational Basis of 'Irrational' Drug Use: Pharmaceuticals in the Context of Development." In Anthropology in Public Health: Bridging Differences in Culture and Society, edited by Robert A. Hahn, 165-182. Oxford: Oxford University Press.
120. Faden, Ruth, Tom Beauchamp, and Nancy King. 1986. The History and Theory of Informed Consent. New York: Oxford University Press.
121. Farmer, Paul. 1999. Infections and Inequalities: The Modern Plagues. Berkeley and Los Angeles: University of California Press.
122. Farmer, Paul. 2002. "Can Transnational Research Be Ethical in the Developing World?" Lancet 360(9342):1266-1302.
123. Farmer, Paul. 2003. Pathologies of Power: Health, Human Rights, and the New War on the Poor. Berkeley and Los Angeles: University of California Press.
124. Finn, P. B. 2006. "The Negotiation and Development of a Clinical Trial Agreement." Journal of Biolaw and Business 9(2):21-27.
125. "Fiocruz culpa tradução incompleta por experimento com iscas humanas." Folha Online. Retrieved July 27, 2007, from http://www1.folha.uol.com.br/folha/cotidiano/ult95u116511.shtml.
126. Fischer, Michael M. J. 2001. "Ethnographic Critique and Technoscientific Narratives: The Old Mole, Ethical Plateaux, and the Governance of Emergent Biosocial Polities." Culture, Medicine and Psychiatry 25(4):355-393.
127. Fischer, Michael M. J. 2003. Emergent Forms of Life and the Anthropological Voice. Durham, NC: Duke University Press.
128. Fisher, Jill A. 2009. Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials. New Brunswick, NJ: Rutgers University Press.
129. Fox, Renee. 1959. Experiment Perilous: Physicians and Patients Facing the Unknown. Glencoe, IL: Free Press.
130. Franklin, Sarah. 1995. "Science as Culture, Cultures of Science." Annual Review of Anthropology 24:163-185.
131. Friedman, Thomas. 2005. The World Is Flat: A Brief History of the Twenty-first Century. New York: Farrar, Straus and Giroux.
132. Frost, L., M. R. Reich, and T. Fujisaki. 2002. "A Partnership for Ivermectin: Social Worlds and Boundary Objects." In Public-Private Partnerships for Public Health, edited by M. R. Reich, 87-113. Cambridge: Harvard University Press.
133. "Future Developments for Gaucher Disease including Enzyme Replacement Therapy." 2002. Gaucher News. Retrieved from http://www.gaucher.org.uk/furthermarch2002.htm.
134. Galvão, Jane. 2002. "Access to Antiretroviral Drugs in Brazil." Lancet 360:1862-1865.
135. Garnier, J. P. 2005. Contribution at conference, Advancing Enterprise. February 4. Retrieved February 4, 2005, from http://www.hm-treasury.gov.uk/media/30C/C2/Dr_JP_Garnier.pdf.
136. Garrett, Laurie. 2007. "The Challenge of Global Health." Foreign Affairs 86 (1):14-38.
137. Geertz, Clifford. 1984 [2000]. "Anti Anti-Relativism." In Available Light: Anthropological Reflections on Philosophical Topics, 42-67. Princeton: Princeton University Press.
138. Geertz, Clifford. 2001. "Life among the Anthros." New York Review of Books 48(2):18-22.
139. Geissler, P. W., A. Kelly, B. Imoukhuede, and R. Pool. 2008. "'He is now like a brother, I can even give him some blood'-Relational Ethics and Material Exchanges in a Malaria Vaccine 'Trial Community' in the Gambia." Social Science and Medicine 67(5):696-707.
140. Geissler, P. W., and C. Molyneux, eds. In press. African Trial Community: Ethno-graphies and Histories of Medical Research in Africa. New York: Berghahn Publishers.
141. GFHR [Global Forum for Health Research]. 2004. The 10/90 Report on Health Research 2003-2004. Geneva: GFHR. Also at www.globalforumhealth.org/pages/index.asp.
142. Gilhooley, Margaret. 2007. "Vioxx's History and the Need for Better Procedures and Better Testing." Seton Hall Law Review 37:941-956.
143. Global Pharmaceuticals Sales Statistics. 2006. Retrieved August 5, 2007, from http://www.lesechos.fr/medias/2007/0323//300153931.pdf.
144. Godlee, Fiona. 2006. "An International Standard for Disclosure of Clinical Trial Information" (editorial). British Medical Journal 332:1107-1108.
145. Goodman, Jordan, Anthony McElligott, and Lara Marks. 2003.Useful Bodies: Humans in the Service of Medical Science in the Twentieth Century. Baltimore: Johns Hopkins University Press.
146. Goozner, Merrill. 2004. The $800 Million Pill: The Truth behind the Cost of New Drugs. Berkeley and Los Angeles: University of California Press.
147. Gorman, James. 2004. "The Altered Human Is Already Here." New York Times, April 6, F1.
148. Gostin, Lawrence. 2007. "Global Regulatory Strategies for Tobacco Control." Journal of the American Medical Association 298(17):2057-2058.
149. Graham, David. 2004. Statement of David J. Graham before the Senate Finance Committee Hearing, 108th Congress, "The FDA, Merck, and Vioxx: Putting Safety First." Washington, DC.
150. Greene, Jeremy. 2006. Prescribing by Numbers: Drugs and the Definition of Disease. Baltimore: Johns Hopkins University Press.
151. Greenhouse, Carol. 2005. "Hegemony and Hidden Transcripts: The Discursive Arts of Neoliberal Legitimation." American Anthropologist 107(3):356-368.
152. Greenhouse, Carol. 2006. "Fieldwork on Law." Annual Review of Law and Social Science 2:187-210.
153. Greenslit, Nathan. 2005. "Depression and Consumption: Psychopharmaceuticals, Branding, and New Identity Practices." Culture, Medicine and Psychiatry 29(4):477-501.
154. "The Growing Power of the Fortune 500." 2006. Working Life. Labor Research Association. Downloaded August 5, 2007, from http://www.workinglife.org/wiki/. Guidance for Industry: Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions. 2002. Washington, DC: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.
155. Guillemin, Jeanne. 1998. "Bioethics and the Coming of the Corporation to Medicine." In Bioethics and Society, edited by Raymond de Vries and Janardon Subedi, 60-77. Upper Saddle River, NJ: Prentice Hall.
156. Halperin, Daniel. 2008. "Putting a Plague in Perspective" (op-ed). New York Times. Available at http://www.nytimes.com/2008/01/01/opinion/01halperin.html.
157. Halpern, Sydney. 2001. "Constructing Moral Boundaries: Public Discourse on Human Experimentation in Twentieth-Century America." In Bioethics in Social Context, edited by Barry Hoffmaster, 69-89. Philadelphia: Temple University Press.
158. Halpern, Sydney. 2004. Lesser Harms: The Morality of Risk in Medical Research. Chicago: University of Chicago Press.
159. Hardon, Anita. 1987. "The Use of Modern Pharmaceuticals in a Filipino Village: Doctors' Prescription and Self-Medication." Social Science and Medicine 25(3):277-292.
160. Harkness, Jon M. 1996. "Research behind Bars: A History of Nontherapeutic Research on American Prisoners." Ph. D. diss., University of Wisconsin, Mad ison.
161. Harris, Gardiner. 2004a. "Drug Trial Finds Big Health Risks in 2nd Painkiller." New York Times, December 18, 2004.
162. Harris, Gardiner. 2004b. "New Study Links Pfizer's Bextra, Similar to Vioxx, to Heart Attacks." New York Times, November 10, 2004.
163. Hayden, Cori. 2007. "Taking as Giving: Bioscience, Exchange, and the Politics of Benefit-Sharing." Social Studies of Science 37(5):729-758.
164. Hawkins, J. S., and E. J. Emanuel. 2005. "Clarifying Confusions about Coercion." Hastings Center Report 35(5):16-19.
165. Health in the Americas. 1998. "Brazil." Pan American Health Organization. Retrieved from http://www.paho.org/English/HIA1998/Brazil.pdf.
166. Healy, David. 1999. The Antidepressant Era. Cambridge: Harvard University Press.
167. Healy, David. 2004. Let Them Eat Prozac: The Unhealthy Relationship between the Pharmaceutical Industry and Depression. New York: New York University Press.
168. Healy, David. 2006. "The New Medical Oikumene." In Global Pharmaceuticals: Ethics, Markets, Practices, edited by Adriana Petryna, Andrew Lakoff, and Arthur Kleinman, 61-85. Durham, NC: Duke University Press.
169. Heimer, Carol. 2008. "Expertise and Flexibility in Medicine and Law (What Happens When HIV Guidelines Are Hardened by Law)." Unpublished manuscript.
170. Heller, Jean. 2000. "Syphilis Victims in U.S. Study Went Untreated for Forty Years." In Tuskegee's Truths: Rethinking the Tuskegee Syphilis Study, edited by Susan M. Reverby, 116-119. Chapel Hill: University of North Carolina Press.
171. Hilts, Philip. 2004. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation. Chapel Hill: University of North Carolina Press.
172. Hirschman, Albert. 1970. Exit, Voice, and Loyalty: Responses to Decline in Firms, Organizations, and States. Cambridge: Harvard University Press.
173. Hirschman, Albert. 1980. "Morality and the Social Sciences: A Durable Tension." Acceptance Paper, the Frank E. Seidman Distinguished Award in Political Economy. Memphis, TN: P. K. Seidman Foundation, October.
174. Hoffman, Sharona. 2000. "Beneficial and Unusual Punishment: An Argument in Support of Prisoner Participation in Clinical Trials." Indiana Law Review 33:475-515.
175. Hornblum, Allen. 1991. Acres of Skin: Human Experiments at Holmesburg Prison. New York: Routledge.
176. Horrobin, David. 2002. "Effective Clinical Innovation: An Ethical Imperative." Lancet 359(9320):1857-1858.
177. Howell, J. D., and R. A. Hayward. 2003. "Writing Willowbrook, Reading Willowbrook: The Recounting of a Medical Experiment." In Using Bodies: Humans in the Service of Medical Science in the Twentieth Century, edited by J. Goodman, A. McElligott, and L. Marks, 190-213. Baltimore: Johns Hopkins University Press.
178. Huibers, Marcus J. H., Gijs Bleijenberg, Anna J.H.M. Beurskens, Ijmert Kant, J. André Knottnerus, Daniëlle A.W.M. van der Windt, Ellen Bazelmans, and Constant P. van Schayck. 2004. "An Alternative Trial Design to Overcome Validity and Recruitment Problems in Primary Care Research." Family Practice 21:213-218.
179. Humbert, Marc, Olivier Sitbon, and Gérald Simonneau. 2004. "Treatment of Pulmonary Arterial Hypertension." New England Journal of Medicine 351(14): 1425-1436.
180. Humpl, Tilman, Janette T. Reyes, Helen Holtby, Derek Stephens, and Ian Adatia. 2005. "Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension." Circulation 111:3274-3280.
181. Hunt, Nancy. 1999. A Colonial Lexicon: Of Birth Ritual, Medicalization, and Mobility in the Congo. Durham, NC: Duke University Press. Institute of Medicine. 2006. "The Future of Drug Safety: Promoting and Protecting the Health of the Public." Washington, DC: National Academies Press.
182. Iyalomhe, G. B., and P. A. Imomoh. 2007. "Ethics of Clinical Trials." Nigerian Journal of Medicine 16(4):301-306.
183. Jacob, Marie-Andrée, and Annelise Riles. 2007. "The New Bureaucracies of Virtue: Introduction." PoLAR 30(2):181-192.
184. Jain, Sarah Lochlann. 2006. Injury: The Politics of Product Design and Safety Law in the United States. Princeton: Princeton University Press.
185. Jasanoff, Sheila. 1998. The Fifth Branch: Science Advisors as Policymakers. Cambridge: Harvard University Press.
186. Jasanoff, Sheila. 2006. "Experiments without Borders: Biology in the Labs of Life." http://www.lse.ac.uk/collections/LSEPublicLecturesAndEvents/pdf/20060615_Jasanoff.pdf.
187. Jonas, Hans. 1969. "Philosophical Reflections on Human Experimentation." Daedalus 98:219-247.
188. Jones, James H. 1981 [1993]. Bad Blood: The Tuskegee Syphilis Experiment. New York: Free Press.
189. Jonsen, Albert R., and Jeff Stryker, eds. 1993. The Social Impact of AIDS in the United States. Washington, DC: National Academy of Sciences.
190. Juni, P., L. Nartey, S. Reichenbach, R. Sterchi, P. A. Dieppe, and M. Egger. 2004. "Risk of Cardiovascular Events and Rofecoxib: Cumulative Meta-Analysis." Lancet 364(9450):2021-2029.
191. Kahn, Jonathan. 2004. "How a Drug Becomes 'Ethnic': Law, Commerce, and the Production of Racial Categories in Medicine." Yale Journal of Health Policy, Law, and Ethics 4:1-46.
192. Kahn, J. P., A. C. Mastroianni, and J. Sugarman, eds. 1998. Beyond Consent: Seeking Justice in Research. New York: Oxford University Press.
193. Kalmbach, K. C., and Philip Lyons, Jr. 2003. "Ethical and Legal Standards for Research in Prisons." Behavioral Sciences and the Law 21(5):671-686.
194. Kassirer, Jerome P. 2004. On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health. New York: Oxford University Press.
195. Kent, David M., Mkaya Mwamburi, et al. 2004. "Clinical Trials in Sub-Saharan Africa and Established Standards of Care: A Systematic Review of HIV, Tuberculosis, and Malaria Trials." Journal of the American Medical Association 292:237-242.
196. Kim, Jim Yong, Joia S. Mukherjee, Michael L. Rich, Kedar Mate, Jaime Bayona, and Mercedes Becerra. 2003. "From Multidrug-Resistant Tuberculosis to DOTS Expansion and Beyond: Making the Most of a Paradigm Shift." Tuberculosis 83(3):59-65.
197. Kimmelman, J. 2007. "Stable Ethics: Enrolling Non-treatment-refractory Volunteers in Novel Gene Transfer Trials." Molecular Therapy 15(11):1904-1906.
198. Klein, Naomi. 2007. The Shock Doctrine: The Rise of Disaster Capitalism. New York: Metropolitan Books.
199. Klein, Rudolf. 1980. "Models of Man and Models of Policy: Reflection on Exit, Voice, and Loyalty Ten Years Later." Milbank Memorial Fund Quarterly 58(3): 416-429.
200. Kleinman, Arthur. 1981. Patients and Healers in the Context of Culture. Berkeley and Los Angeles: University of California Press.
201. Kleinman, Arthur. 1999. "Moral Experience and Ethical Reflection: Can Ethnography Reconcile Them? A Quandary for 'The New Bioethics.'" Daedalus 128(4):69-99.
202. Konrad, Monica. 2007. "International Biodiplomacy and Global Ethical Forms: Relations of Critique between Public Anthropology and Science in Society." Anthropological Quarterly 80(2):325-353.
203. Krall, Hannah. 1996. To Steal a March on God. New York: Routledge.
204. Krimsky, Sheldon. 2003. Science in the Private Interest. Lanham, MD: Rowman & Littlefield.
205. Kuebler, Chris, Walter S. Nimmo, Joseph H. von Rickenbach, Dennis Gillings, Allan T. Morgan, Candace Kendle, and Paul S. Covington. 2002. "Ethics and Industry-Sponsored Research." Canadian Medical Association Journal 166 (5):580-581.
206. Kuo, Wen-Hua. 2005. "Japan and Taiwan in the Wake of Bio-Globalization: Drugs, Race and Standards." Ph.D. diss., Massachusetts Institute of Technology.
207. Laine, Christine, Richard Horton, Catherine D. DeAngelis, Jeffrey M. Drazen, Frank A. Frizelle, Fiona Godlee, Charlotte Haug, Paul C. Hébert, Sheldon Kotzin, Ana Marusic, Peush Sahni, Torben V. Schroeder, Harold C. Sox, Martin B. Van Der Weyden, and Freek W. A. Verheugt. 2007. "Clinical Trial Registration-Looking Back and Moving Ahead." New England Journal of Medicine 356(26):2734-2736.
208. Lakoff, Andrew. 2006a. "High Contact: Gifts and Surveillance in Argentina." In Global Pharmaceuticals: Ethics, Markets, Practices, edited by Adriana Petryna, Andrew Lakoff, and Arthur Kleinman, 111-136. Durham, NC: Duke University Press.
209. Lakoff, Andrew. 2006b. Pharmaceutical Reason: Knowledge and Value in Global Psychiatry. Cambridge: Cambridge University Press.
210. Lansbury, Peter. 2004. "An Innovative Drug Industry? Well, No." Washington Post, November 16, B02.
211. Lasagna, Louis. 1962. "Clinical Analysis of Medical Fads." New York Times Magazine 24(22):31-33.
212. Lasagna, Louis. 1977. "Prisoner Subjects and Drug Testing." Federation Proceedings 36(10):2349-2351.
213. Latour, Bruno. 1998. "Give Me a Laboratory and I Will Raise the World." In The Science Studies Reader, edited by Mario Biagioli, 258-275. New York: Routledge.
214. Latour, Bruno. 2005. "From Realpolitik to Dingpolitik or How to Make Things Public." In Making Things Public: Atmospheres of Democracy, edited by Bruno Latour and Peter Weibel, 14-43. Cambridge, MA: MIT Press.
215. Lederer, Susan. 1997. Subjected to Science: Human Experimentation in America before the Second World War. Baltimore, MD: Johns Hopkins University Press.
216. Lederman, Rena. 2006. "Introduction: Anxious Borders between Work and Life in a Time of Bureaucratic Ethics Regulation." American Ethnologist 33(4):477-481.
217. Lemmens, Trudo, and Benjamin Freedman. 2000. "Ethics Review for Sale? Con-flict of Interest and Commercial Research Review Boards." Milbank Quarterly 78:547-584.
218. Lemmens, Trudo, and Ron Bouchard. 2007. "Mandatory Clinical Trial Registration: Rebuilding Trust in Medical Research." In Global Forum for Health Research, Global Forum Update on Research for Health, vol. 4, Equitable Access: Research Challenges for Health in Developing Countries. London: Pro-Book Publishing.
219. Lerner, Barron H. 2007. "Subjects or Objects? Prisoners and Human Experimentation." New England Journal of Medicine 356(18):1806-1807.
220. Levine, C., R. Faden, C. Grady, D. Hammerschmidt, L. Eckenwiler, J. Sugarman; Consortium to Examine Clinical Research Ethics. 2004. "The Limitations of 'Vulnerability' as a Protection for Human Research Participants." American Journal of Bioethics 4(3):44-49.
221. Lewin, Tamar. 2001. "Families Sue Pfizer on Test of Antibiotic." New York Times, August 30, C1.
222. Lexchin, Joel. 2001. "Lifestyle Drugs: Issues for Debate." Canadian Medical Association Journal 164(10):1449-1451.
223. Lexchin, Joel, Lisa A. Bero, Benjamin Djulbegovic, and Otavio Clark. 2003. "Pharmaceutical Industry Sponsorship and Research Outcome and Quality: Systematic Review." British Journal of Medicine 326:1167-1170. Light, Donald. 2008. "Reply to Dimasi, Hansen, and Grabowski." Journal of Health Politics, Policy and Law 33(2):325-327.
224. Light, Donald, and Rebecca Warburton. 2005. "Extraordinary Claims Require Extraordinary Evidence." Journal of Health Economics 24(5):1030-1033.
225. Lindenbaum, Shirley. 1978. Kuru Sorcery: Disease and Danger in the New Guinea Highlands. New York: McGraw-Hill.
226. Lippman, Abby. 2006. "The Inclusion of Women in Clinical Trials: Are We Asking the Right Questions?" March 2006. Toronto, ON: Women and Health Protection, http://www.whp-apsf.ca/en/documents/doc_index.html, downloaded November 7, 2007.
227. Lock, Margaret. 2001. Twice Dead: Organ Transplants and the Reinvention of Death. Berkeley and Los Angeles: University of California Press.
228. Love, James. "Health Care and Intellectual Property: The Orphan Drug Act." http://www.cptech.org/ip/healthorphan.
229. Lowy, Ilana. 2000. "Trustworthy Knowledge and Desperate Patients: Clinical Tests for New Drugs from Cancer to AIDS." In Living and Working with the New Medical Technologies: Intersections of Inquiry, edited by Margaret Lock, Alan Young, and Alberto Cambrosio, 49-82. Cambridge: Cambridge University Press.
230. Lurie, Peter, and Sidney M. Wolfe. 1998. "Unethical Trials of Interventions to Reduce Perinatal Transmission of the Human Immunodeficiency Virus in Developing Countries." New England Journal of Medicine 337(12):853-855.
231. Lurie, Peter, and Sidney M. Wolfe. 2000. "Letter to the National Bioethics Advisory Commission regarding Their Report on the Challenges of Conducting Research in Developing Countries (HRG Publication #1545)." Accessed January 2007 at http://www.citizen.org/publications/release.cfm?ID=6746.
232. Lustgarten, Abraham. 2005. "Drug Testing Goes Offshore." Fortune, August 8, 57-61.
233. Macklin, Ruth. 1999. Against Relativism: Cultural Diversity and the Search for Ethical Universals in Medicine. Oxford: Oxford University Press.
234. Macklin, Ruth. 2004. Double Standards in Medical Research in Developing Countries. Cambridge: Cambridge University Press.
235. Mansfield, Peter. 2006. "E-DRUG: Access to Essential Medicines as a Human Right." Retrieved from http://www.essentialdrugs.org/edrug/archive/200607/msg00078.php.
236. Marks, Harry. 1997. The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990. Cambridge: Cambridge University Press.
237. Marks, Harry. 2000. "Where Do Ethics Come From? The Role of Disciplines and Institutions." Paper presented at the conference Ethical Issues in Clinical Trials, University of Alabama at Birmingham, February 25.
238. Marks, Harry. 2002. Commentary. Third Annual W.H.R. Rivers Workshop, Global Pharmaceuticals: Ethics, Markets, Practices. Harvard University, May 19-21.
239. Marks, Harry. 2008. "Making Risks Visible: The Science and Politics of Adverse Drug Reactions." Unpublished manuscript.
240. Marks, Lara. 2001. Sexual Chemistry: A History of the Contraceptive Pill. New Haven: Yale University Press.
241. Marshall, Patricia, and Barbara Koenig. 2004. "Accounting for Culture in a Globalized Ethics." Journal of Law, Medicine, and Ethics 32(2):252-266.
242. Masters, B., and M. Kaufman. 2004. "Painful Withdrawal for Makers of Vioxx." Washington Post, October 18, A01.
243. Mathews, Anna, and Barbara Martinez. 2004. "Warning Signs: E-Mails Suggest Merck Knew Vioxx's Dangers at Early Stage-As Heart-Risk Evidence Rose, Officials Played Hardball; Internal Message: 'Dodge!'-Company Says 'Out of Context'." Wall Street Journal, November 1, A1.
244. McCabe, Christopher, Aki Tsuchiya, Karl Claxton, and James Raftery. 2006. "Drugs for Exceptionally Rare Diseases: A Commentary on Hughes et al." University of Sheffield, School of Health and Related Research, Discussion Paper Series. Retrieved from http://www.shef.ac.uk/content/1/c6/01/87/47/0602FT.pdf.
245. Meadows, Michelle. 2002. "The FDA's Review Process: Ensuring Drugs Are Safe and Effective." FDA Consumer 36 (July-August).
246. Medawar, Charles, and Anita Hardon. 2004. Medicines out of Control? Anti-depressants and the Conspiracy of Goodwill. Amsterdam: Aksant Academic Publishers.
247. Meinert, Curtis. 1988. "NIH Multicenter Investigator-Initiated Trials: An Endangered Species?" Controlled Clinical Trials 9:97-102.
248. Meinert, Curtis. 1995. "The Inclusion of Women in Clinical Trials." Science 269:795-796.
249. Meldrum, Marcia. 1994. "Departures from the Design: The Randomized Clinical Trial in Historical Context, 1946-1970." Ph.D. diss., State University of New York at Stonybrook.
250. Melrose, Dianna. 1982. Bitter Pills" Medicines and the Third World Poor. Oxford: Oxfam.
251. Meng, Joyce. 2007. "Expanding Global Health Access: A Comparative Analysis of Pharmaceutical Corporate Social Responsibility Initiatives." Unpublished manuscript.
252. Merz, Jon F., David Magnus, Mildred K. Cho, and Arthur Caplan. 2002. "Protecting Subjects' Interests in Genetics Research." American Journal of Human Genetics 70(4):965-971.
253. Messeder, Ana Márcia. 2005. "Política Pública de Assistência Farmacêutica-Medicamentos de Dispensação em Caráter Excepcional." PowerPoint presentation. Departamento de assistência farmacêutica e insumos estratégicos/SCTIE/MS. August 26.
254. Milne, C., and C. Paquette. 2004. "Meeting the Challenge of the Evolving R&D Paradigm: What Role for the CRO?" American Pharmaceutical Outsourcing. Available at www.americanpharmaceuticaloutsourcing.com.
255. Milosz, Czeslaw. 2004. Second Space. New York: Ecco.
256. Mirowski, Philip, and Esther-Mirjam Sent. 2007. "The Commercialization of Science and the Response of STS." In Handbook of Science, Technology and Society Studies, edited by E. Hackett, O. Amsterdamska, J. Wajcman, and Michael Lynch, 343-379. Cambridge, MA: MIT Press.
257. Mirowski, Philip, and Robert van Horn. 2005. "The Contract Research Organi-zation and the Commercialization of Scientific Research." Social Studies of Science 35(4):503-548.
258. Misra, Kavita. 2000. "Productivity of Crises: Disease, Scientific Knowledge and State in India." Economic and Political Weekly 35(43-44):3885-3897.
259. Mitford, Jessica. 1973. "Experiments behind Bars: Doctors, Drug Companies, and Prisoners." Atlantic Monthly 23:64-73.
260. Moran, Mary. 2005. "A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We Need." PLoS Medicine 2(9):302.
261. Moreno, Jonathan D. 1998. "Convenient and Captive Populations." In Beyond Consent: Seeking Justice in Research, edited by J. P. Kahn, A. C. Mastroianni, and J. Sugarman, 111-130. New York: Oxford University Press.
262. Moreno, Jonathan D. 2000. Undue Risk: Secret State Experiments on Humans. London: Routledge.
263. Moreno, Jonathan D. 2004. "Bioethics and the National Security State." Journal of Law, Medicine, and Ethics 32(2):198-208.
264. Moynihan, Ray, and Alan Cassels. 2005. Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients. New York: Nation Books.
265. Moynihan, Ray, Iona Heath, and David Henry. 2002. "Selling Sickness: The Pharmaceutical Industry and Disease Mongering." British Medical Journal 324:886-891.
266. Murthy, V. H., H. M. Krumholtz, and C. D. Gross. 2004. "Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities." Journal of the American Medical Association 291:2720-2726.
267. Nagengast, Carole, Michal Buchowski, and Edouard Conte, eds. 2001. Poland beyond Communism: "Transition" in Critical Perspective. Fribourg, Switzerland: University Press.
268. National Bioethics Advisory Commission. 2000. Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries. Bethesda, MD: National Bioethics Advisory Commission.
269. Nguyen, Vinh-Kim. 2005. "Antiretroviral Globalism, Biopolitics, and Therapeutic Citizenship." In Global Assemblages: Technology, Politics, and Ethics as Anthropological Problems, edited by A. Ong and S. J. Collier, 124-144. Oxford: Blackwell.
270. Nichter, Mark. 2008. Global Health: Why Cultural Perceptions, Social Representations, and Biopolitics Matter. Tucson: University of Arizona Press.
271. Nichter, Mark, and Nancy Vuckovic. 1994. "Agenda for an Anthropology of Pharmaceutical Practice." Social Science and Medicine 39(11):1509-1525.
272. Notícias do CONASS. 2007. Retrieved July 7, 2007, from http://www.conass.org.br/.
273. OIG [Office of Inspector General, Department of Health and Human Services]. 2001. "The Globalization of Clinical Trials: A Growing Challenge in Protecting Human Subjects." Boston: Office of Evaluation and Inspections. Retrieved September 22, 2004, from http://oig.hhs.gov/organization/OIGmission.html.
274. OIG [Office of Inspector General, Department of Health and Human Services]. 2007. "The Food and Drug Administration's Oversight of Clinical Trials." Retrieved September 30, 2007, from http://oig.hhs.gov/oei/reports/oei-01-06-00160.pdf.
275. Okie, S. 2006. "Fighting HIV-Lessons from Brazil." New England Journal of Medicine 354(19):1977-1981.
276. Ong, Aihwa, and Stepen Collier, eds. 2005. Global Assemblages: Technology, Politics, and Ethics as Anthropological Problems.Malden, MA: Blackwell Publishing.
277. Ost, David. 2005. The Defeat of Solidarity: Anger and Politics in Postcommunist Europe. Ithaca: Cornell University Press.
278. Packard, Randall. 2007. The Making of a Tropical Disease: A Short History of Malaria. Baltimore: Johns Hopkins University Press.
279. Parexel. 2005. Pharmaceutical R&D Statistical Sourcebook 2005/2006. Waltham, MA: Parexel International.
280. Parexel. 2008. Bio/Pharmaceutical R&D Statistical Sourcebook 2007/2008. Walt-ham, MA: Parexel International.
281. Peltzman, Sam. 1973. "An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments." Journal of Political Economy 81(5):1049-1091.
282. PEPFAR [The President's Emergency Plan for AIDS Relief]. 2006. Second Annual Report to Congress, U.S. Department of State. Released by the Office of the U.S. Global AIDS Coordinator February 8, 2006, 107. Available at http://www.state.gov/s/gac/rl/61284.htm, downloaded November 2007.
283. Petryna, Adriana. 2002. Life Exposed: Biological Citizens after Chernobyl. Princeton: Princeton University Press.
284. Petryna, Adriana. 2005. "Ethical Variability: Drug Development and the Globalization of Clinical Trials." American Ethnologist 32(2):183-197.
285. Petryna, Adriana. 2007. "Clinical Trials Offshored: On Private Sector Science and Public Health." BioSocieties 2:21-40.
286. Petryna, Adriana, and Arthur Kleinman. 2006. "The Pharmaceutical Nexus: An Introduction." In Global Pharmaceuticals: Ethics, Markets, Practices, edited by Adriana Petryna, Andrew Lakoff, and Arthur Kleinman, 1-33. Durham, NC: Duke University Press.
287. Petryna, Adriana, Andrew Lakoff, and Arthur Kleinman, eds. 2006. Global Pharmaceuticals: Ethics, Markets, Practices. Durham, NC: Duke University Press.
288. Pharmbiosys Main Page. 2007. Retrieved March 3, 2007, from http://www.pharmbiosys.com. The Physician Compensation Report. July 2003. Marblehead, MA: HCPro.
289. Piantados, Steven, and Jenet Wittes. 1993. "Politically Correct Clinical Trials." Controlled Clinical Trials 14:562-567.
290. Picon, Paulo. 2006. "Role of HTA in Evaluation and Regulation of New Technology in Emergent Economies: A Public Health Policy Perspective." Power-Point presentation delivered at Health Technology Assessment International, Adelaide, July 5.
291. Picon, Paulo, K. M. Amaral, Guilherme Sander, and J. G. Reis. 2005. "Implementation of Brazilian Guidelines for Treatment of Hepatitis C: A Cost-Saving Intervention in the South of Brazil." Italian Journal of Public Health 2:259.
292. Picon, Paulo, and A. Beltrame. 2002. Protocolos Clínicos e Diretrizes Terapêuticas: Medicamentos Excepcionais, vol. 1. Porto Alegre: Grafica e Editora Pallotti.
293. Picon, Paulo, A. Beltrame, Andry Costa, Guilherme Sander, K. M. Amaral, and B. C. Krug. 2005. "Brazilian Guidelines for High-Cost Drugs: The Development of National Evidence-Based Public Health Policy." Italian Journal of Public Health 3:150-151.
294. Picon, Paulo, A. F. Costa, R. Kuchenbecker, and A. Beltrame. 2002. "Peginterferon alfa-2b plus Ribavirin for Chronic Hepatitis." Lancet 359(9302):263.
295. Picon, Paulo, Andry Costa, and Guilherme Sander. 2005. Protocolos Clínicos UNIMED-POA. Porto Alegre: Nova Prova.
296. Picon, Paulo, I. V. Schwartz, C. Krug, R. Guigliani, L.C.B. Lima, and J. G. Reis. 2005. "Maintaining Clinical Efficacy with Cost-Reduction in the Treatment of Gaucher Disease: An Example of Successful Experience in the South of Brazil." Italian Journal of Public Health 2:259. PIH Guide to the Community-Based Treatment of HIV in Resource-Poor Settings. 2006. 2nd ed. Available at http://model.pih.org/.
297. Pine, Frances, and Haldis Haukanes, eds. 2005. Social Security, Vulnerability and People at Risk: Gender and Generation in the Former Socialist Countries of Europe and Central Asia. Centre for Women's and Gender Research Series, vol. 17. University of Bergen.
298. Pocock, Stuart. 2002. "The Pro's and Con's of Non-Inferiority (Equivalence) Trials." In The Science of the Placebo: Toward an Interdisciplinary Research Agenda, edited by Harry A. Guess, Arthur Kleinman, John W. Kusek, and Linda W. Engel, 236-248. London: BMJ Books.
299. Pogge, Thomas. 2006. "Harnessing the Power of Pharmaceutical Innovation." In The Power of Pills: Social, Ethical, and Legal Issues in Drug Development, Marketing, and Pricing, edited by Jillian Claire Cohen, Patricia Illingworth, and Udo Schuklenk, 142-149. London: Pluto Press. Downloadable at http://www.colbio.org.mx/simposium_colbio/Thomas_Pogge.pdf.
300. Pogge, Thomas. 2007. "Could Globalization Be Good for World Health?" Global Justice: Theory and Practice Rhetoric 1:1-10.
301. Pollack, Andrew. 2007a. "Pricing Pills by the Results." New York Times, July 14, C1, C4.
302. Pollack, Andrew. 2007b. "Death in Gene Therapy Treatment Is Still Unexplained." New York Times, September 18, A22.
303. Pollack, Andrew. 2008. "Cutting Dosage of Costly Drug Spurs a Debate." New York Times, March 16, A1, A24.
304. Prakash, Gyan. 1999. Another Reason: Science and the Imagination of Modern India. Princeton: Princeton University Press.
305. PricewaterhouseCoopers. 2006. "Clinical Trials in Poland-Main Barriers to Industry Development." http://www.pwc.com/pl/eng/ins-sol/publ/2006/ph_badania_kliniczne.pdf.
306. Psaty, Bruce. 2004. Statement of Prof. Bruce Psaty before the Senate Finance Committee Hearing, 108th Congress, "The FDA, Merck, and Vioxx: Putting Safety First." Washington, DC.
307. Psaty, B. M., and C. D. Furberg. 2005. "COX-2 Inhibitors-Lessons in Drug Safety." New England Journal of Medicine 352:1135.
308. Psaty, Bruce M., and Richard A. Kronmal. 2008. "A Case Study Based on Documents from Rofecoxib Litigation." Journal of the American Medical Association 299(15):1813-1817.
309. Quintanilla, Ray. 2004. "Anger over Puerto Rico's Pill Test Lingers." thebatt.com. Texas A&M. Retrieved from http://www.thebatt.com/media/paper657/news/2004/04/12/.
310. Rabinow, Paul. 1996. Essays on the Anthropology of Reason. Princeton: Princeton University Press.
311. Rabinow, Paul. 2003. Anthropos Today: Reflections on Modern Equipment. Princeton: Princeton University Press.
312. Ramiah, Ilavenil, and Michael R. Reich. 2005. "Public-Private Partnerships and Antiretroviral Drugs for HIV/AIDS: Lessons from Botswana." Health Affairs 24(2):545-551.
313. Ramos, Joana D. 2004. "Gleevec Patient Assistance Program USA." Retrieved from http://ramoslink.info/pubs/GlivecPAP.pdf.
314. Ramos, Joana D. 2005. "New Definition of 'Patient Assistance Program' in Brazil." Healthy Skepticism International News 23:1.
315. Rapp, Rayna. 1999. Testing Women, Testing the Fetus: The Social Impact of Amniocentesis in America. New York: Routledge.
316. Rasmussen, Nicholas. 2005. "Drugs and Globalisation." Metascience 14:73-77.
317. Redfield, Peter. 2006. "A Less Modest Witness: Collective Advocacy and Motivated Truth in a Medical Humanitarian Movement." American Ethnologist (33)1:3-26.
318. RedFearn, Suz. 2008. "We're Not Sweatshops: ACRO Responds to NEJM." http://www.clinpage.com/article/acro_responds_to_nejm/.
319. Reich, Michael R., ed. 2002. Public-Private Partnerships for Public Health. Cambridge, MA: Harvard Center for Population and Development Studies.
320. Relman, Arnold, and Marcia Angell. 2002. "How the Drug Industry Distorts Medicine and Politics: America's Other Drug Problem." New Republic, December 16, 27-41.
321. Rettig, Richard. 2000. "The Industrialization of Clinical Research." Health Affairs 19(2):129-146.
322. Reverby, Susan, ed. 2000. Tuskegee's Truths: Rethinking the Tuskegee Syphilis Study. Chapel Hill: University of North Carolina Press.
323. Rheinberger, Hans-Jorg. 1995. "From Experimental Systems to Cultures of Experimentation." In Concepts, Theories, and Rationality in the Biological Sciences, edited by G. Wolters, J. Lennox, and P. McLaughlin. Pittsburgh, PA: University of Pittsburgh Press.
324. Riles, Annelise. 2000. The Network Inside Out. Ann Arbor: University of Michigan Press.
325. Riles, Annelise. 2004. "The Network Inside Out." In The Anthropology of Development and Globalization: From Classical Political Economy to Contemporary Neo-liberalism, edited by Marc Edelman and Angelique Haugerud, 262-269. Ho-bo ken, NJ: Wiley-Blackwell.
326. Riles, Annelise. 2005. "Skepticism, Intimacy and the Ethnographic Subject: Human Rights as Legal Knowledge." American Anthropologist, December 2005. Available at SSRN: http://ssrn.com/abstract=742569.
327. Riles, Annelise. 2006. "Anthropology, Human Rights, and Legal Knowledge: Culture in the Iron Cage." American Anthropologist 108(1):52-65.
328. Ringelblum, Emanuel. 1974. Notes from the Warsaw Ghetto. New York: Schocken.
329. Rivkin-Fish, Michele. 2005. Women's Health in Post-Soviet Russia: The Politics of Intervention. Bloomington: Indiana University Press.
330. Roitman, Janet. 2004. Fiscal Disobedience: An Anthropology of Economic Regulation in Central Africa. Princeton: Princeton: University Press.
331. Rosenberg, Roger N. 2003. "Translating Biomedical Research to the Bedside: A National Crisis and a Call to Action" (editorial). Journal of the American Medical Association 289(10):1305-1306.
332. Rothman, David. 1991. Strangers at the Bedside: A History of How Law and Bioethics Transformed Medical Decision Making. New York: Basic Books.
333. Rothman, David. 2000. "The Shame of Medical Research." New York Review of Books 47(19):60-64.
334. Rothman, Sheila, and David Rothman. 2005. The Willowbrook Wars. New York: Aldine.
335. Sachs, Jeffrey. 2006. The End of Poverty: Economic Possibilities for Our Time. New York: Penguin.
336. Sackett, David, and Andrew Oxman. 2003. "HARLOT plc: An Amalgama tion of the World's Two Oldest Professions." British Medical Journal 327:1442-1445.
337. Salter, Brian, Melinda Cooper, and Amanda Dickins. 2006. "China and the Global Stem Cell Bioeconomy: An Emerging Political Strategy?" Regenerative Medicine 1(5):671-683.
338. Samsky, Ari. 2008. "Pharmaceutical Philanthropy: An Anthropological Study of Practices and Values Shaping Drug Donations." Ph.D. diss., Princeton University.
339. Sander, Guilherme, Paulo Picon, F. D. Fuchs, A. Beltrame, and R. R. De Souza. 2003. "PEG-Interferon versus Conventional Interferon and Liver Fibrosis: Do We Have Evidence of Superiority?" Gastroenterology 124(2):584.
340. Sassen, Saskia. 2006. Territory, Authority, Rights: From Medieval to Global Assemblages. Princeton: Princeton University Press.
341. Scheper-Hughes, Nancy. 1992. Death without Weeping: The Violence of Everyday Life in Brazil. Berkeley and Los Angeles: University of California Press.
342. Scheper-Hughes, Nancy. 2004. "Parts Unknown: Undercover Ethnography of the Organs-Traf-ficking Underworld." Ethnography 5(1):29-74.
343. Schmidt, Maria Inês, and Bruce B. Duncan. 2004. "Academic Medicine as a Resource for Global Health: The Case of Brazil." British Medical Journal 329: 753-754.
344. Schmit, Julie. 2005. "Costs, Regulations Move More Drug Tests Outside USA." USA Today, May 16.
345. Schuklenk, Udo, and R. Ashcroft. 2000. "International Research Ethics." Bioethics 14(2):158-172.
346. "Seminário discute ações judiciais sobre medicamentos excepcionais." 2005. Agência Minas. Retrieved from http://www.agenciaminas.mg.gov.br/detalhe_noticia.php?cod_noticia=5812.
347. Sewankambo, Nelson. 2004a. "Academic Medicine Needs a Global Agenda." British Medical Journal 329:751-752.
348. Sewankambo, Nelson. 2004b. "Academic Medicine and Global Health Responsibilities." British Medical Journal 329:752-753.
349. Shah, Sonia. 2007. Body Hunters: How the Drug Industry Tests Its Products on the World's Poorest Patients. New York: The New Press.
350. Shuchman, Miriam. 2007. Commercializing Clinical Trials-Risks and Benefits of the CRO Boom." New England Journal of Medicine 357(14):1365-1368.
351. Sieder, Rachel, Line Schjolden, and Alan Angell, eds. 2005. The Judicialization of Politics in Latin America. New York: Palgrave Macmillan.
352. Silverman, M., P. R. Lee, and M. Lydecker. 1982. Prescriptions for Death: The Drugging of the Third World. Berkeley and Los Angeles: University of California Press.
353. Sim, Ida, and Don E. Detmer. 2005. "Beyond Trial Registration: A Global Trial Bank for Clinical Trial Reporting." PLoS Medicine 2(11):1090-1092.
354. Simon, Gregory. 2006. "The Antidepressant Quandary-Considering Suicide Risk When Treating Adolescent Depression." New England Journal of Medicine 355(26):2722-2723.
355. Sinackevich, Nick, and Jean-Pierre Tassignon. 2004. "Speeding the Critical Path." Applied Clinical Trials 13(1):42-48.
356. Sivaramakrishnan, K. 2005. Introduction to "Moral Economies, State Spaces, and Categorical Violence." American Anthropologist 107(3):321-330.
357. Smith, Jane. 1990. Patenting the Sun: Polio and the Salk Vaccine. New York: William Morrow.
358. Steinbrook, Robert. 2005. "Gag Clauses in Clinical-Trial Agreements." New England Journal of Medicine 352(21):2160-2162.
359. Stephens, Trent D., and Rock Brynner. 2001. Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine. Cambridge, MA: Perseus Publishing.
360. Stiglitz, Joseph. 2002. Globalization and Its Discontents. W. W. Norton & Com-pany.
361. Strathern, Marilyn. 1992. After Nature: English Kinship in the Late Twentieth Century. Cambridge: Cambridge University Press.
362. Sunder Rajan, Kaushik. 2005. "Subjects of Speculation: Emergent Life Sciences and Market Logics in the United States and India." American Anthropologist 107(1):19-30.
363. Sunder Rajan, Kaushik. 2006. Biocapital: The Constitution of Postgenomic Life. Durham, NC: Duke University Press.
364. Sunder Rajan, Kaushik. 2007. "Experimental Values." New Left Review 45(May-June):67-88.
365. Sung, Nancy S., William F. Crowley Jr., Myron Genel, Patricia Salber, Lewis Sandy, Louis M. Sherwood, Stephen B. Johnson, Veronica Catanese, Hugh Tilson, Kenneth Getz, Elaine L. Larson, David Scheinberg, E. Albert Reece, Harold Slavkin, Adrian Dobs, Jack Grebb, Rick A. Martinez, Allan Korn, and David Rimoin. 2003. "Central Challenges Facing the National Clinical Research Enterprise." Journal of the American Medical Association 289:1278-1287.
366. Temple, Robert. 2002. "Placebo-Controlled Trials and Active Controlled Trials: Ethics and Inference." In The Science of the Placebo: Toward an Inter disciplinary Research Agenda, edited by Harry A. Guess, Arthur Kleinman, John W. Kusek, and Linda W. Engel, 209-227. London: BMJ Books.
367. Thiers, Fabio, Anthony Sinskey, and Ernst Berndt. 2007. "Trends in the Globalization of Clinical Trials." Nature Reviews Drug Discovery 7:13-14.
368. Timimi, Sami. 2007. Review of Global Pharmaceuticals: Ethics, Markets, Practices. British Journal of Psychiatry 190:367.
369. Timmermans, Stefan, and Marc Berg. 2003. The Gold Standard: The Challenge of Evidence-Based Medicine. Philadelphia: Temple University Press.
370. Topol, Eric J. 2004. "Failing the Public Health-Rofecoxib, Merck, and the FDA." New England Journal of Medicine 351:1707.
371. Topol, Eric J. 2005. "Arthritis Medicines and Cardiovascular Events-'House of Coxibs.'" Journal of the American Medical Association 293(3):366-368.
372. Topol, Eric, and David Blumenthal. 2005. "Physicians and the Investment Industry." Journal of the American Medical Association 294(15):1897-1898.
373. Toulmin, Stephen. 1982. "How Medicine Saved the Life of Ethics." Perspectives in Biology and Medicine 25(4):736-750.
374. Toulmin, Stephen. 1987. "National Commission on Human Experimentation: Procedures and Outcomes." In Scientific Controversies: Case Studies in the Resolution and Closure of Disputes in Science and Technology, edited by H. Tristram Engelhardt Jr. and Arthur L. Caplan, 599-615. Cambridge: Cambridge University Press.
375. Town Topics. 2004. Obituary of G. Hein Besselaar. Retrieved from http://www.towntopics.com/mar2404/obits.html.
376. "Treatment of Lysosomal Storage Disorders" (editorial). 2003. British Medical Journal 327:462-463.
377. "Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No.10." 1949. Nuremberg Code. No. 10, 181-182. Washington DC: U.S. Government Printing Office.
378. Tsing, Anna Lowenhaupt. 2004. Friction: An Ethnography of Global Connection. Princeton: Princeton University Press
379. U.S. Department of Health and Human Services, Food and Drug Administration. 1998. "Investigational New Drug Applications and New Drug Applications, Final Rule." Federal Register 63(8):6854-6862.
380. U.S. Department of Health and Human Services, Food and Drug Administration, et al. 2005. Guidance for Industry Collection of Race and Ethnicity Data in Clinical Trials. Available at http://www.fda.gov/CbER/gdlns/racethclin.htm.
381. U.S. Food and Drug Administration. 2001. "International Conference on Harmonisation: Choice of Control Group and Related Issues in Clinical Trials." Federal Register 66:24390-24391.
382. U.S. Food and Drug Administration. 2002. "The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective." Retrieved May 12, 2006, from http://www.fda.gov/fdac/features/2002/402_drug.html.
383. U.S. Food and Drug Administration. 2007. "FDA's Critical Path Initiative-Science Enhancing the Health and Well-Being of All Americans." Retrieved March 2007, from http://www.fda.gov/oc/initiatives/criticalpath/initiative.html.
384. U.S. Food and Drug Administration, Office of Orphan Products Development. "OOPD Program Overview." Retrieved from http://www.fda.gov/orphan/progovw.htm.
385. U.S. National Institutes of Health. 2006. "Glossary of Clinical Trial Terms." National Library of Medicine. Retrieved August 7, 2007, from http://clinicaltrials.gov/ct/info/glossary.
386. U.S. National Institutes of Health. 2007. "An Introduction to Clinical Trials." National Library of Medicine. Retrieved August 7, 2007, from http://clinicaltrials.gov/ct/info/whatis#phases.
387. "Uso de cobaias humanas no Amapá causa horror, diz senador da Folha." 2006. Retrieved July 27, 2007, from http://www1.folha.uol.com.br/folha/ciencia/ult306u14130.shtml.
388. Van der Geest, Sjaak, and Susan Reynolds Whyte, eds. 1988. The Context of Medicines in Developing Countries: Studies in Pharmaceutical Anthropology. Boston: Kluwer Academic Publishers.
389. Van der Geest, Sjaak, Susan Reynolds Whyte, and Anita Hardon. 1996. "The Anthropology of Pharmaceuticals: A Biographical Approach." Annual Review of Anthropology 25:153-178.
390. Varmus, Harold, and David Satcher. 1996. "Ethical Complexities of Conducting Research in Developing Countries." New England Journal of Medicine 337 (14):1003-1005.
391. Vastag, Brian. 2000. "Helsinki Discord? A Controversial Declaration." Journal of the American Medical Association 284(23):2983-2985.
392. Vaughan, Megan. 1992. Curing Their Ills: Colonial Power and African Illness. Stanford: Stanford University Press.
393. Vitoria, Cesar G., Jean-Pierre Habicht, and Jennifer Bryce. 2004. "Evidence-Based Public Health: Moving beyond Randomized Trials." American Journal of Public Health 94(3):400-405.
394. Wardell, William, and Louis Lasagna. 1975. Regulation and Drug Development. Washington, DC: American Enterprise Institute for Public Policy Research.
395. Wedel, Janine. 1992. The Unplanned Society: Poland during and after Communism. New York: Columbia University Press.
396. Wendler, David, Kington Raynard, Jennifer Madans, Gretchen Van Wye, Heidi Christ-Schmidt, Laura A. Pratt, Otis W. Brawley, Cary P. Gross, and Ezekiel Emanuel. 2006. "Are Racial and Ethnic Minorities Less Willing to Participate in Health Research?" PLoS Medicine 3(2):0201-0210.
397. Wertheimer, Alan. 2006. Coercion. Princeton: Princeton University Press.
398. Whitmarsh, Ian. 2008. Biomedical Ambiguity: Race, Asthma, and the Contested Meaning of Genetic Research in the Caribbean. Ithaca: Cornell University Press.
399. Whyte, Susan Reynolds, Michael A. Whyte, Lotte Meinert, and Betty Kyaddondo. 2006. "Treating AIDS: Dilemmas of Unequal Access in Uganda." In Global Pharmaceuticals: Ethics, Markets, Practices, edited by Adriana Petryna, Andrew Lakoff, and Arthur Kleinman, 240-263. Durham, NC: Duke University Press.
400. Winter, Jane, and Jane Baguley. 2006. Outsourcing Clinical Development: Strategies for Working with CROs and Other Partners. Aldershot, UK: Ashgate Publishing.
401. Wood, Alastair J. J. 2006. "A Proposal for Radical Changes in the Drug-Approval Process." New England Journal of Medicine 355:618, 619, 622.
402. Woolf, Steven H., and Robert E. Johnson. 2005. "The Break-Even Point: When Medical Advances Are Less Important Than Improving the Fidelity with Which They Are Delivered." Annals of Family Medicine 3:545-552.
403. World Medical Association. 2000. "Declaration of Helsinki. Ethical Principles for Medical Research involving Human Subjects." Journal of the American Medical Association 284(23):3043-3045.
404. Young, Iris. 2004. "Responsibility and Historic Injustice." Paper presented at the School of Social Science Thursday Seminar, Institute for Advanced Study, Princeton, New Jersey, February 19.
405. Zarin, Deborah A., Nicholas C. Ide, Tony Tse, William R. Harlan, Joyce C. West, and Donald A. B. Lindberg. 2007. "Issues in the Registration of Clinical Trials." Journal of the American Medical Association 297(19):2112-2120.
406. Zarin, D. A., and A. Keselman. 2007. "Registering a Clinical Trial in Clinical Trials." Chest 131(3):909-912.